 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|
   |
| RXMD Announces Best February Results for Revenue and Number of Prescriptions in Company History |
|
 Hot Stock to Watch |
Company: Progressive Care Inc. (OTCQB: RXMD)
|
Last:
Price: 0.0674
Change (%): - 0.0026 (3.71)
Volume: 178,614 |
 |
Progressive Care Inc. Announces Strongest February in Company History
MIAMI, FL, March 21, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced further growth year-over-year in revenue and number of prescriptions filled for February 2019.
In February, the company reported a total of $1.7 million in net revenue, a 17% increase from the same month last year, and a 36% increase in prescriptions filled during the same month last year, totaling nearly 26,719 prescriptions filled. Despite industry headwinds through reimbursement compression, network restriction, and formulary reduction, the Company continues its upward growth trend for revenues and prescriptions filled. The Company credits this growth to superior performance reviews and promotion of value-added healthcare service offerings.
“February was another big month for us. Progressive Care exceeded February, 2018 prescription fillings and is moving forward on major initiatives,” said S. Parikh Mars, CEO of Progressive Care. “We are currently wrapping up the annual report and working through the acquisition process with licensing and contracting agencies. We are on track to double our revenues post acquisition of FPRX and are confident that 2019 will lead to continued growth, more record-breaking months, and even bigger milestones as we continue our mission to revolutionize the pharmacy industry.”
Continue Reading
|
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
